Amicus Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.07 | -$0.06 | -$0.06 |
| Q2 2024 | 2 | -$0.06 | -$0.05 | -$0.05 |
| Q3 2024 | 2 | $0.00 | $0.00 | $0.00 |
| Q4 2024 | 7 | $0.00 | $0.03 | $0.02 |
| Q1 2025 | 5 | -$0.00 | -$0.00 | -$0.00 |
| Q2 2025 | 4 | $0.03 | $0.03 | $0.03 |
| Q3 2025 | 4 | $0.05 | $0.06 | $0.05 |
| Q4 2025 | 4 | $0.08 | $0.09 | $0.08 |
| Q1 2026 | 3 | $0.00 | $0.00 | $0.00 |
| Q2 2026 | 3 | $0.00 | $0.00 | $0.00 |
| Q3 2026 | 3 | $0.00 | $0.00 | $0.00 |
| Q4 2026 | 3 | $0.00 | $0.00 | $0.00 |
| Q1 2027 | 3 | $0.00 | $0.00 | $0.00 |
| Q2 2027 | 3 | $0.00 | $0.00 | $0.00 |
| Q3 2027 | 3 | $0.00 | $0.00 | $0.00 |
| Q4 2027 | 3 | $0.00 | $0.00 | $0.00 |
Amicus Therapeutics, Inc. Earnings Date And Information
Amicus Therapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $0.1 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.02. The company had revenue of 141.52 M for the quarter and had revenue of 399.36 M for the year. Amicus Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-0.51 diluted earnings per share) and currently has a price-to-earnings ratio of -27.79. Amicus Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based on prior year's report dates.
Amicus Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | $0.08 | -$0.02 | -0.1 | $134.93 M | $141.52 M |
| 08/08/2024 | Q2 2024 | $0.05 | -$0.05 | -0.11 | $121.21 M | $126.67 M |
| 05/09/2024 | Q1 2024 | -$0.06 | -$0.16 | -0.1 | $110.40 M | |
| 02/28/2024 | Q4 2023 | -$0.06 | -$0.12 | -0.06 | $115.08 M | |
| 11/08/2023 | Q3 2023 | -$0.08 | -$0.07 | 0.01 | $102.30 M | $103.50 M |
| 08/08/2023 | Q2 2023 | -$0.12 | -$0.15 | -0.03 | $89.83 M | $94.50 M |
| 05/10/2023 | Q1 2023 | -$0.13 | -$0.18 | -0.05 | $86.27 M | |
| 03/01/2023 | Q4 2022 | -$0.13 | -$0.20 | -0.07 | $88.10 M | |
| 11/07/2022 | Q3 2022 | -$0.19 | -$0.12 | 0.07 | $84.21 M | $81.69 M |
| 08/04/2022 | Q2 2022 | -$0.23 | -$0.21 | 0.02 | $85.87 M | $80.73 M |
| 05/10/2022 | Q1 2022 | -$0.30 | $78.72 M | |||
| 02/24/2022 | Q4 2021 | -$0.14 | -$0.31 | -0.17 | $82.15 M | |
| 11/09/2021 | Q3 2021 | -$0.18 | -$0.19 | -0.01 | $80.11 M | $79.55 M |
| 08/05/2021 | Q2 2021 | -$0.21 | -$0.19 | 0.02 | $73.16 M | $77.41 M |
| 05/10/2021 | Q1 2021 | -$0.23 | -$0.25 | -0.02 | $66.40 M | |
| 03/01/2021 | Q4 2020 | -$0.24 | -$0.28 | -0.04 | $70.57 M | |
| 11/05/2020 | Q3 2020 | -$0.20 | -$0.25 | -0.05 | $64.81 M | $67.44 M |
| 08/10/2020 | Q2 2020 | -$0.26 | -$0.20 | 0.06 | $62.46 M | $62.35 M |
| 05/07/2020 | Q1 2020 | -$0.28 | -$0.35 | -0.07 | $60.53 M | |
| 03/02/2020 | Q4 2019 | -$0.26 | -$0.35 | -0.09 | $55.29 M |
Amicus Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Amicus Therapeutics, Inc.'s earnings date?
Amicus Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 26th, 2025 based off last year's report dates.
-
Did Amicus Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Amicus Therapeutics, Inc. (:FOLD) reported $0.1 earnings per share (EPS) to beat the analysts' consensus estimate of $0.08 by $0.02.
-
How can I listen to Amicus Therapeutics, Inc.'s earnings conference call?
The conference call for Amicus Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Amicus Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Amicus Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Amicus Therapeutics, Inc. generate each year?
Amicus Therapeutics, Inc. (:FOLD) has a recorded annual revenue of $399.36 M.
-
How much profit does Amicus Therapeutics, Inc. generate each year?
Amicus Therapeutics, Inc. (:FOLD) has a recorded net income of $399.36 M. Amicus Therapeutics, Inc. has generated $-0.51 earnings per share over the last four quarters.
-
What is Amicus Therapeutics, Inc.'s price-to-earnings ratio?
Amicus Therapeutics, Inc. (:FOLD) has a price-to-earnings ratio of -27.79 and price/earnings-to-growth ratio is -0.41.
